Sellas Life Sciences Group (SLS) closed at $7.86 on November 13, 2026, down 2.1% from the previous close, on volume of 10,086,674 shares (30-day average 6,312,817).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts | Position |
|---|---|---|---|---|---|
| 1 | Oct 21, 2026 | Ratio Call Spread 1 by 1.12 | 15-Jan-2711 : 15[1.12x] C | 53,000 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | ||||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
SELLAS: Favorable Risk-Reward Ahead of Phase 3 REGAL Readout; $30 Price Target Unchanged
TipRanks (Sat, 14-Nov 11:35 AM ET)
Sellas Life Sciences shares jump as key leukemia trial results near
Seeking Alpha News (Thu, 12-Nov 10:38 PM ET)
SELLAS Life Sciences GAAP EPS of -$0.05 in-line
Seeking Alpha News (Thu, 12-Nov 4:11 PM ET)
SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
SELLAS spotlights Phase 2 SLS009 combo data with 57% ORR in TP53-mutated AML ahead of ASH 2026
Market Chameleon (Wed, 4-Nov 4:42 AM ET)
Globe Newswire (Wed, 4-Nov 9:00 AM ET)
SELLAS hits the 80th event in its Phase 3 REGAL AML study, setting up a final analysis this quarter
Market Chameleon (Wed, 28-Oct 5:15 AM ET)
Globe Newswire (Wed, 28-Oct 8:35 AM ET)
Market Chameleon (Mon, 28-Sep 4:39 AM ET)
Globe Newswire (Fri, 25-Sep 1:00 PM ET)
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Sellas Life Sciences Group trades on the NASDAQ stock market under the symbol SLS.
As of November 13, 2026, SLS stock price declined to $7.86 with 10,086,674 million shares trading.
SLS has a beta of 0.89, meaning it tends to be less sensitive to market movements. SLS has a correlation of 0.01 to the broad based SPY ETF.
SLS has a market cap of $1.59 billion. This is considered a Small Cap stock.
In the last 3 years, SLS traded as high as $15.88 and as low as $.50.
The top ETF exchange traded funds that SLS belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
SLS has outperformed the market in the last year with a return of +438.4%, while the SPY ETF gained +13.4%. However, in the most recent history, SLS shares have underperformed the stock market with its stock returning -36.4% in the last 3 month period and -18.8% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
SLS support price is $7.39 and resistance is $8.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLS shares will trade within this expected range on the day.
